Quick Facts

• Primary Use: Management of mild to moderate essential hypertension (high blood pressure).
• Therapeutic Goal: To achieve and maintain lowered blood pressure levels.
• Patient Group: Approved for use in adult individuals.

---

What Lercanidipine Actavis Treats: Main Uses and Benefits

Lercanidipine Actavis is a medication approved for the therapeutic management of mild to moderate essential hypertension in adults. Essential hypertension is a clinical term for high blood pressure that does not have an identifiable secondary cause.

The core therapeutic effect of this treatment is to help achieve a reduction in elevated blood pressure. Maintaining blood pressure within a clinically appropriate range is intended to support overall cardiovascular health and may contribute to mitigating health risks associated with persistent high blood pressure.

This medication is utilized either as a sole treatment (monotherapy) or in combination with other agents for individuals whose blood pressure levels are not sufficiently addressed by a single medication. The benefit of this therapeutic approach is focused on blood pressure control over a 24-hour period.

Lercanidipine Actavis is typically prescribed for adults aged 18 and over to treat high blood pressure (hypertension).

However, it is not suitable for everyone. Before starting this medication, a healthcare provider must be informed of the patient’s full medical history and current medications.

---

Contraindications and Groups to Avoid

Lercanidipine Actavis must not be used by individuals who:

• Have an allergy or hypersensitivity to lercanidipine or any other medicine in the dihydropyridine class (e.g., amlodipine, nifedipine).
• Suffer from certain serious heart conditions, including uncontrolled heart failure, obstruction of blood flow from the heart, or unstable angina.
• Have had a heart attack (myocardial infarction) in the previous month.
• Have severe liver or kidney problems, including patients undergoing dialysis.
• Are pregnant or breastfeeding.
• Are taking certain medications, including cyclosporin or strong CYP3A4 inhibitors (such as certain antifungal drugs, macrolide antibiotics, or antivirals).

Additionally, the use of grapefruit or grapefruit juice must be avoided due to the potential for increasing the drug's effects. The medication is also not recommended for use in children and adolescents under 18 years due to a lack of data on efficacy and safety.

Lercanidipine Actavis Interactions with other medicines and products

This section details official interaction information for Lercanidipine, primarily concerning its metabolism by the CYP3A4 enzyme and potential pharmacodynamic effects, as documented by regulatory authorities.

Classification	Interacting Agents / Products	Regulatory Constraint
Contraindicated Combinations	Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Ritonavir, Erythromycin, Clarithromycin)	Co-administration is prohibited
	Immunosuppressant: Ciclosporin	Co-administration is prohibited
	Grapefruit or Grapefruit Juice	Must not be taken

Lercanidipine's primary metabolic pathway involves the CYP3A4 enzyme, meaning substances that affect this enzyme can significantly alter the medicine's concentration in the body.

• CYP3A4 Inducers: Co-administration with enzyme inducers, such as certain anticonvulsants (e.g., Phenytoin, Carbamazepine) and Rifampicin, should be approached with caution as these may reduce Lercanidipine plasma levels and potentially lessen the intended antihypertensive effect.
• Exposure Modification: The drug Simvastatin should be administered in the evening if Lercanidipine is taken in the morning; no interaction is expected with this time separation. Lercanidipine has been observed to increase the exposure (AUC) of Simvastatin.
• Pharmacodynamic Effects: Concomitant use with other antihypertensive drugs (e.g., Diuretics, ACE Inhibitors) may result in an additive hypotensive effect. Alcohol should be avoided as it may potentiate the vasodilating effects of Lercanidipine.
• Population Note: The antihypertensive effect may be enhanced in patients with moderate hepatic impairment, which is a population-specific consideration noted in the regulatory documentation.

Blocking Calcium Entry to Relax Arterial Walls

Lercanidipine exerts its primary effect by selectively blocking the L-type Voltage-Gated Calcium Channels (mathbfCamathbfv1.2) located in the membranes of arteriolar smooth muscle cells. This inhibition restricts the necessary influx of extracellular calcium ions ( Ca^2+), directly interrupting the signals required for the muscle cells to contract and tighten. This initial molecular action initiates a cascade leading to arteriolar vasodilation, a physiological change characterized by the widening of the vessel lumen.

Sustained Reduction in Peripheral Resistance

The resulting relaxation of the arterial walls decreases the mechanical opposition to blood flow, a systemic effect known as lowering the Total Peripheral Resistance. Lercanidipine's high lipophilicity allows it to partition into the cell membrane, forming a membrane depot that enables a slow, continuous release. This sustained interaction allows the effect of vasodilation to be maintained for approximately 24 hours, resulting in a consistent and gradual modulation of pressure dynamics.

Official Administration Guidelines for Lercanidipine Actavis

Lercanidipine Actavis is a film-coated tablet for oral use in adults. The administration of this medicine is structured by specific guidelines regarding dosage, frequency, and timing to optimize its effectiveness as an antihypertensive agent.

---

Standard Dosing and Schedule

The standard adult dosing regimen begins with a 10 mg dose once daily. The maximum recommended dose is 20 mg once daily. Any increase from the starting dose is guided by a gradual approach: dose adjustment should occur only after a minimum period of approximately two weeks, corresponding to the time required for the maximal antihypertensive effect to become apparent.

Lercanidipine must be taken at the same time each day, preferably in the morning. A critical administration constraint is that the tablet must be swallowed whole with water at least 15 minutes before a meal.

---

Special Population Use and Restrictions

While no routine dosage adjustment is mandated for older adults or individuals with mild to moderate renal or hepatic impairment, treatment initiation or dose increase to 20 mg must be approached with special care. The medicine is not recommended for use in the pediatric population (under 18 years of age) due to a lack of clinical data.

Regarding co-ingestion, the product must not be administered with grapefruit or grapefruit juice, as this can alter the medicine's systemic availability.

Lercanidipine Actavis: Recent Clinical Evidence

---

Evidence for Use in Essential Hypertension

Initial clinical research on Lercanidipine was conducted for its use in managing high blood pressure. These studies included short-term, randomized controlled trials (RCTs), where the medicine was evaluated in adults with mild to moderate essential hypertension. Some trials used placebo or different blood pressure medications as comparators. Research examined outcomes related to outcomes monitoring physiological strain or stress, specifically monitoring the change in seated systolic and diastolic blood pressure over defined time intervals. The evidence collected contributes to the overall understanding of Lercanidipine in research settings. Studies explored how the medicine performed in older adult patients and those with co-existing conditions such as type 2 diabetes or mild-to-moderate renal impairment.

---

Outcomes Beyond Blood Pressure Control and Long-Term Data

Research has also explored outcomes related to major functional measures in studies conducted over longer periods. This includes monitoring data related to major cardiovascular and cerebrovascular events (such as stroke occurrence) over several years. These longer-term observations was associated with data patterns that contribute to the broader evidence landscape related to the condition. The main efficacy research exploring short-term symptom changes was generally confined to short-term periods (four to twelve weeks). Long-term outcomes have not been fully characterized within highly controlled RCTs, with evidence often being derived from settings with varying symptom burdens using observational studies.

---

Understanding Evidence Gaps and Limitations

Data are still emerging regarding the long-term impact on hard clinical outcomes (e.g., mortality) when compared directly against certain other established classes of anti-hypertensive medicines in dedicated, large RCTs. The regulatory assessment for the Actavis product relied on demonstrating bioequivalence and a review of existing published clinical data, not new large-scale efficacy trials. The evidence quality varies across studies; some trials in patient subgroups were open-label or non-comparative, meaning certainty remains low for findings drawn exclusively from these designs. Research does not determine whether an individual will respond similarly to the group averages observed.

Key Studies & References Public Assessment Report (for Lercanidipine Mylan) - covers bioequivalence and regulatory basis for generic approval

Common questions about Lercanidipine Actavis (FAQ)

Q: What is Lercanidipine Actavis used for?

A: Lercanidipine Actavis is a type of medicine known as a calcium channel blocker. It is indicated for the treatment of mild to moderate essential hypertension (high blood pressure) in adults. It functions by relaxing blood vessels, which in turn may help to lower blood pressure.

Q: How does Lercanidipine Actavis work?

A: Lercanidipine is a dihydropyridine calcium antagonist. This class of medicine works by blocking the influx of calcium into smooth muscle cells in the walls of blood vessels. This action causes the blood vessels to widen and relax, which is understood to reduce peripheral vascular resistance and thereby lower blood pressure.

Q: Can I stop taking Lercanidipine Actavis if my blood pressure improves?

A: Individuals should not abruptly stop taking Lercanidipine Actavis without consulting a qualified healthcare provider. Blood pressure control is often necessary for long periods, and stopping the treatment prematurely may result in a rise in blood pressure, even if no immediate symptoms are present. Maintaining treatment consistency as directed is typically essential for managing hypertension effectively.

Q: What should I do if I miss a dose?

A: If a dose is missed, individuals should generally take the dose as soon as they remember, unless it is almost time for the next scheduled dose. If it is close to the time for the next dose, the missed dose should be skipped, and the regular dosing schedule should be resumed. Doubling the dose to make up for a missed one is not recommended. Always consult the patient information leaflet or a pharmacist for specific advice.

Q: What are some common side effects of Lercanidipine Actavis?

A: Like many medications, Lercanidipine Actavis may be associated with side effects, although not everyone experiences them. Common side effects reported in clinical trials and post-marketing surveillance may include: headache, dizziness, flushing, and swelling of the ankles (peripheral edema). If these or any other concerning effects are experienced, individuals should discuss them with their healthcare provider.

Q: Does Lercanidipine Actavis interact with other medications?

A: Lercanidipine Actavis may interact with certain other medications. The concurrent use of Lercanidipine with potent inhibitors of the enzyme CYP3A4, such as ketoconazole, or with certain immunosuppressants like ciclosporin, is typically contraindicated. Furthermore, caution may be warranted with other blood pressure medicines. Patients should inform their doctor or pharmacist about all other medicines, supplements, or herbal products they are currently taking prior to starting Lercanidipine Actavis.

Storage and Disposal of Lercanidipine Actavis

Lercanidipine Actavis must be stored according to specific conditions to maintain product stability and safety, as defined in regulatory labeling.

Storage Requirements

Condition	Requirement
Temperature	Do not store the medicine above 30 C.
Protection	Store in the original package to protect contents from moisture.
Container Rule	If supplied in a container (e.g., HDPE bottle), keep it tightly closed to prevent moisture ingress.
Child Safety	Keep the medicine out of the sight and reach of children.
Stability	Do not use the tablets after the stated expiry date.

Disposal Instructions

Official instructions require that unused or expired Lercanidipine Actavis must not be disposed of via general household waste or by pouring into wastewater. Any waste material must be handled and discarded in accordance with local pharmaceutical requirements.